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Multiple and complex genetic and epigenetic abnormalities 
underlie the multistage transformation of normal cells into 
cancerous ones. Among these abnormalities are the activation 
of oncogenes and loss of function of tumour suppressor 
genes. Besides these abnormalities, it is becoming evident that 
specific cancers are dependent on one or a few genes for their 
malignant phenotype, and this could be their ‘Achilles heel’. This 
survival dependency of cancer cells on an activated oncogene 
or inactivation of tumour suppressor gene is called ‘oncogene 
addiction’ and may well be a potential way to provide more 
rational molecular targeted therapy. This strategy needs to 
integrate new approaches into the clinical setting in order to 
characterise the state of oncogene addiction and accordingly, 
apply more effective and selective anti-cancer therapies.
oncogene aDDicTion: DefiniTion anD suPPorTing eviDence
Human cancer develops through a multistage process which 
can take decades to evolve. Such a process involves progressive 
accumulation of mutations and epigenetic aberrations in 
multiple genes.1-4 For this reason, many cancer cells feature 
extensive disruptions in their genome. However, some human 
cancers seem to depend on one or a few genes to maintain 
their malignant phenotype. It is as if the cancer cells become 
‘addicted’ to these genes and their products. Indeed, deactivating 
the implicated oncogene or re-activating the tumour suppressor 
gene can inhibit proliferation and growth of the cancer cells. 
Such behaviour has led to the introduction of the concept of 
‘oncogene addiction’, first described by Weinstein et al. in 1997.1
Since then, several research papers have supported the 
role of oncogene addiction in the proliferation and survival of 
different types of cancer cells. Supporting evidence emerged 
mostly from studies carried out using (i) human cancer cell 
lines, (ii) genetically engineered mouse models of human cancer, 
and from (iii) clinical trials involving specific molecular targeted 
agents.
(i) sTuDies in human cancer cell lines
Throughout the years, established human cancer cell lines 
have been used as experimental models of human cancers. 
to address the role of oncogene addiction, some of these cell 
lines were treated with an antisense oligonucleotide, or an 
RNA interference (RNAi), directed to (and thus inhibiting) the 
respective oncogene. For instance, some investigations5-7 targeted 
the cyclins, which play a key role in regulating the progression of 
cells through the phases of the cell cycle. one such investigation 
was carried out by Arber et al., who showed that the stable 
transfection of a cyclin D1 antisense construct in human colon 
cancer cells is associated with growth inhibition and decreased 
tumourigencity. Kornmann et al., who applied a similar 
approach, but used human pancreatic cancer cells instead, 
observed comparable results. Besides cyclin D1, other cyclins 
have also been targeted. Indeed, Li et al., through the use of a 
siRNA (small interfering RNA), showed that the depletion of 
cyclin e promotes apoptosis, and thus blocks cell proliferation, 
in hepatocellular carcinoma cells.
oncogene addiction studies have targeted other oncogenes 
as well. For instance, Colomer et al.8 showed that erbB-2 
antisense oligonucleotides inhibit the proliferation of breast 
cancer cells. Similarly, inhibition of β-Catenin,9 K-rasmut,10 
K-rasv12,11 MItF,12 and Mutant B-Raf,13 all of which are involved 
in complex cell signalling pathways, has been shown to cause 
growth inhibition in other types of cancer cells.
(ii) sTuDies in geneTically engineereD mouse moDels 
of human cancer
Further investigations into oncogene addiction have used 
genetically engineered mouse models of human cancer. Such 
models have been particularly useful when studying the in 
vivo mechanisms of oncogene addiction. oncogenes or their 
products, such as Bcr-Abl,14 c-myc,15-18 erbB-2,19 H-ras,20 K-ras,21 
and Wnt-1,22 have been targeted.
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For instance, Huettner et al. generated a conditional 
transgenic model of BCR-ABL-induced leukaemia, and 
discovered that this oncogene is required for both the 
induction and the maintenance of leukaemia. Similarly, 
D’Cruz et al. expressed the human c-MYC oncogene in the 
mammary epithelium of transgenic mice, and found that 
c-MYC expression results in the formation of mammary 
adenocarcinomas. Subsequently, when this gene was switched 
off, the cancer cells stopped dividing and underwent apoptosis. 
other studies by Chin et al. and Jackson et al. showed that H-ras 
and K-ras are associated with tumour maintenance in skin and 
lung cancer, respectively. together, these, and other studies, have 
shed more light into the concept of oncogene addiction.   
(iii) clinical Trials involving sPecific molecular TargeTeD agenTs
once it was established that oncogene addiction exists, the 
preliminary results obtained from cell culture experiments and 
mouse models were further developed and taken to clinical 
trials. targeted oncogenes included BCR-ABL,23 eGFR,24-26  
HeR-2,27,28 and VeGF.29,30
one such clinical trial investigated the tyrosine kinase 
activity of BCR-ABL. Back in 1990, it was established that this 
kinase blocks apoptosis and triggers unregulated proliferation 
in chronic myeloid leukaemia (CML).31 Thirteen years later, 
imatinib (Gleevec , Novartis), a drug which blocks the tyrosine 
kinase activity of BCR-ABL, was successfully used in a clinical 
trial to treat CML.23 Another tyrosine kinase inhibitor used in 
clinical trials is erlotinib,25,26 which acts on the epidermal growth 
factor receptor (eGFR). eGFR is highly expressed in cancers 
such as non-small cell lung cancer and pancreatic cancer. 
erlotinib is currently marketed in the eu as tarceva  (Roche 
Registration Ltd).
In addition to small-molecule tyrosine kinase inhibitors, 
clinical trials have also made use of monoclonal antibodies. For 
instance, trastuzumab (Herceptin ) is a humanised monoclonal 
antibody that interferes with the human epidermal growth 
factor receptor (HeR2) which is amplified in 25-30% of breast 
cancers.27,28 Similarly, bevacizumab (Avastin ) inhibits vascular 
endothelial growth factor A (VeGF-A) which is a chemical 
signal that stimulates angiogenesis, especially in cancers such as 
breast and colorectal cancers. together, these and other similar 
clinical trials have emphasised the ‘addiction’ of some cancers 
to one or a few genes for the maintenance of the malignant 
phenotype.    To be continued... r
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once iT was esTablisheD ThaT oncogene aDDicTion exisTs, The Preliminary 
resulTs obTaineD from cell culTure exPerimenTs anD mouse moDels 
were furTher DeveloPeD anD Taken To clinical Trials 
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